A re-examination of blood samples from people with early Parkinson’s disease in a Phase 3 trial — in which Dynacirc, a blood pressure medication, failed to slow disease progression — found that those with higher blood levels of Dynacirc were slower to start an antiparkinson therapy and needed lower doses once…
The first Parkinson’s disease patient has been implanted with Newronika‘s AlphaDBS, an innovative deep brain stimulation (DBS) system, in a clinical trial conducted in Italy and Poland. DBS is an established treatment for people with Parkinson’s disease who do not respond adequately to medication. It is a surgical procedure…
Q-State Biosciences has developed a set of optimized antisense oligonucleotides (ASOs) that may serve as potential therapies for Parkinson’s disease patients with specific mutations, the company announced. These ASO candidates are designed for patients carrying mutations in the GBA gene, a key genetic risk factor for the disease’s development. Their…
Clusters of Parkinson’s disease correlated significantly with air quality in urban versus more rural areas, a study spanning the Geneva canton of Switzerland reports, lending support to the idea that air pollution contributes to the disorder. The study, “Geospatial analysis of individual-based Parkinson’s disease data supports…
Alterations in gut microorganisms found in the appendix of people with Parkinson’s disease were associated with elevated digestive bile acids that may play a role in disease development, a study has revealed. The discovery suggests targeting microbial-derived bile acids as a…
Note: This story was updated Feb. 9, 2021, to clarify details surrounding the grant Chronic Care Collaborative received from Adira. Greg Smiley’s world changed abruptly in 2013. He was racing down a mountain road on an outback cycling trip in South Africa, when he hit an obstruction in the road…
Some medications currently used to treat enlarged prostate, such as alpha-1 adrenergic receptor antagonists — called alpha-blockers — might lower the risk of Parkinson’s disease, according to a new study. While more research is needed to fully determine a causal effect of alpha-blockers in treating the neurodegenerative disease, scientists…
Scientists at Cognition Therapeutics have found that compounds that are able to dampen the activity of sigma-2 receptors — receptors that are part of a network that controls the destruction of misfolded proteins — are highly effective at preventing molecule trafficking defects driven by the presence of misfolded alpha-synuclein inside…
Neurocrine Biosciences announced that it is stopping its work with Voyager Therapeutics to further develop VY-AADC (NBIb-1817) as a potential one-time gene therapy for Parkinson’s disease. The therapy, by Voyager and being advanced with Neurocrine’s support, is in a Phase 2 clinical trial (…
Due to negative clinical trial findings, Biogen has discontinued the development of cinpanemab (BIIB054), an investigational medication intended to treat Parkinson’s disease, the company announced in its 2020 investors report. Cinpanemab is a human-derived antibody that targets alpha-synuclein, thought to be one of the key hallmarks of Parkinson’s disease. In the…
Get regular updates to your inbox.
